Physician profile
Bashir A Rawi
NPI 1003964834
$1,144.28
in general payments reported to CMS, 2019-2025
13 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $17.14 · 2021: $82.87 · 2022: $161 · 2023: $23.16 · 2024: $181 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $331.88 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Madrigal Pharmaceuticals | $146.95 | 2025 | Rezdiffra |
| Abbvie INC. | $137.86 | 2019-2025 | |
| Gilead Sciences, INC. | $130.30 | 2025 | Livdelzi |
| Dexcom, INC. | $127.82 | 2022-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $57.11 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.84 | 2025 | |
| Xeris Pharmaceuticals, INC. | $47.54 | 2021-2025 | Gvoke Hypopen |
| Boston Scientific Corporation | $34.31 | 2021 | |
| Hologic Sales and Service, LLC | $24.37 | 2025 | Aptima |
| Teleflex LLC | $23.94 | 2025 | Urolift |
| Novo Nordisk INC | $14.69 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashir Rawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.